Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Portfolio Pulse from Benzinga Newsdesk
Verona Pharma has submitted a New Drug Application (NDA) to the US FDA for approval of ensifentrine, a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).
June 27, 2023 | 7:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verona Pharma's submission of an NDA for ensifentrine could lead to potential FDA approval and increased revenues.
The submission of the NDA for ensifentrine directly impacts Verona Pharma as it could lead to FDA approval, which would allow the company to market and sell the drug in the US. This would result in increased revenues and potentially boost the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100